Generic pharmaceutical companies are looking to Congress to help get the industry out of its recent funk.
Total revenue for the generic drug industry went down 12 percent from June 2016 to June 2017 even though the number of generic prescriptions went up slightly, by 1 percent, the head of a generic industry group told me. And two major generic drugmakers—Mylan NV and Teva Pharmaceutical Industries Ltd.—recently reported disappointing quarterly results. While Mylan and Teva also make branded drug products, they both said in recent financial reports they were experiencing generic drug price erosion.
If the revenue declines continue, “you’re going to see consolidation of the generic companies” and “you’re going to see shortages of products,” Dan Mendelson, chief executive officer of the consulting firm Avalere Health, told me. He also said he is worried about product quality.
Mendelson said “it’s ironic that the generic industry is facing such commercial difficulty just at the time the health-care system needs these product to be widely available.” Generics account for 89 percent of prescriptions dispensed but only 26 percent of total drug costs in the U.S., according to a recent report from the Association for Accessible Medicines (AAM), the generic industry group.
Reasons for the revenue decline include consolidation on the demand side, practices of branded corporations that stifle competition, and more competition among generic products due to more product approvals, Chip Davis, chief executive officer of the AAM, told me.
Davis said there a number of things Congress could do to help, including prohibiting anticompetitive practices by branded drug companies, repealing a penalty in the Medicaid program that unfairly targets generic drugs, and increasing the use of generics in Medicare Part D.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)